Shares of Heron Therapeutics Inc. (NASDAQ:HRTX) traded down 2.1% during trading on Thursday . The stock traded as low as $19.31 and last traded at $19.44, with a volume of 245,176 shares changing hands. The stock had previously closed at $19.85.

Several analysts have recently commented on the stock. Cantor Fitzgerald assumed coverage on shares of Heron Therapeutics in a research report on Monday, May 2nd. They issued a “buy” rating and a $41.00 price target on the stock. Leerink Swann reiterated an “outperform” rating and issued a $33.00 price target on shares of Heron Therapeutics in a research report on Thursday, August 18th. Brean Capital reissued a “buy” rating and set a $55.00 price objective on shares of Heron Therapeutics in a research note on Saturday, August 13th. Zacks Investment Research downgraded shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 3rd. Finally, Cowen and Company reissued a “buy” rating on shares of Heron Therapeutics in a research note on Saturday, July 9th. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Heron Therapeutics currently has an average rating of “Buy” and an average price target of $47.70.

The firm has a 50-day moving average price of $18.58 and a 200-day moving average price of $18.83.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by $0.21. Analysts forecast that Heron Therapeutics Inc. will post ($4.39) earnings per share for the current fiscal year.

In other news, insider Robert Rosen sold 100,000 shares of Heron Therapeutics stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $23.30, for a total value of $2,330,000.00. Following the transaction, the insider now directly owns 102,640 shares of the company’s stock, valued at $2,391,512. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

An institutional investor recently bought a new position in Heron Therapeutics stock. Swiss National Bank bought a new stake in Heron Therapeutics Inc. (NASDAQ:HRTX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 41,200 shares of the biotechnology company’s stock, valued at approximately $1,100,000.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.